ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2459
0,00%
Bitcoin
67.640,46
0,24%
Brent Oil
81,295
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Kinnate Biopharma Inc (KNTE)

  7. Kinnate Biopharma Inc (KNTE) Notícias

KNTE

Kinnate Biopharma (KNTE)

Kinnate Biopharma Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KNTE
DataHoraFonteTítuloCódigoCompanhia
03/04/202410:00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:KNTEKinnate Biopharma Inc
19/03/202417:05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:KNTEKinnate Biopharma Inc
05/03/202419:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
04/03/202419:27Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:KNTEKinnate Biopharma Inc
01/03/202410:53Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:KNTEKinnate Biopharma Inc
01/03/202410:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
01/03/202410:35PR Newswire (US)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
01/03/202410:30GlobeNewswire Inc.Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
16/02/202419:57PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.NASDAQ:KNTEKinnate Biopharma Inc
16/02/202412:46PR Newswire (US)Kuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law FirmNASDAQ:KNTEKinnate Biopharma Inc
16/02/202410:00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:KNTEKinnate Biopharma Inc
16/02/202410:00GlobeNewswire Inc.Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareNASDAQ:KNTEKinnate Biopharma Inc
14/02/202411:21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KNTEKinnate Biopharma Inc
09/11/202318:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNTEKinnate Biopharma Inc
09/11/202318:05GlobeNewswire Inc.Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
18/09/202317:10GlobeNewswire Inc.Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce RestructuringNASDAQ:KNTEKinnate Biopharma Inc
08/08/202317:05GlobeNewswire Inc.Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
13/06/202319:33Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KNTEKinnate Biopharma Inc
12/06/202317:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KNTEKinnate Biopharma Inc
01/06/202317:05GlobeNewswire Inc.Kinnate Biopharma Inc. to Participate in Upcoming Investor ConferencesNASDAQ:KNTEKinnate Biopharma Inc
11/05/202317:27Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KNTEKinnate Biopharma Inc
11/05/202317:05GlobeNewswire Inc.Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
08/05/202318:02Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:KNTEKinnate Biopharma Inc
28/04/202317:18Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:KNTEKinnate Biopharma Inc
28/04/202317:18Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:KNTEKinnate Biopharma Inc
17/04/202315:35GlobeNewswire Inc.Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway GuidanceNASDAQ:KNTEKinnate Biopharma Inc
17/04/202315:30GlobeNewswire Inc.First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant MelanomaNASDAQ:KNTEKinnate Biopharma Inc
06/04/202310:30Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:KNTEKinnate Biopharma Inc
17/03/202317:23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:KNTEKinnate Biopharma Inc
15/03/202317:05GlobeNewswire Inc.Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KNTE

Seu Histórico Recente

BOV
ITUBR26
ITUBR26 Ex:24,5
EU
UMI
Umicore
LSE
58ZQ
Diversity Fd1 E
BOV
RAILS272
RAILS272 Ex:27,16
USOTC
GPKUF
Grand Peak Capital (PK)
BIT
I09743
XS2705562051 20251128 29...
DBI
D1A6
DAX Global BRIC Total Re...
USOTC
GRYRF
Geo Energy Resources (PK)
NASDAQ
FVAODX
Digital World Leaders Op...
TSXV
PESO.WT
Pesorama
BOV
P1DT34R
Prudential Financial
NYSE
XFLX
FundX Investment
TSX
BNC
Purpose Canadian Financi...
NYSE
RF-Z.CL
USOTC
GMAAF
Gama Aviation (PK)
NASDAQ
FLJTLX
Dividend Strength Portfo...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados